BAX Stock Falls Following Q3 Earnings Beat & Sales Miss, '25 EPS View Down

Key Takeaways BAX's Q3 EPS of 69 cents beat estimates by 15%, though revenues of $2.84B missed expectations.BAX's Advanced Surgery sales rose 13%, offsetting softness in Infusion Therapies and IV solutions.BAX cut 2025 EPS view to $2.35-$2.40, prompting a 10.9% pre-market stock decline.Baxter International Inc. (BAX) reported third-quarter 2025 adjusted earnings per share (EPS) of 69 cents, which beat the Zacks Consensus Estimate of 60 cents by 15%. The bottom line declined 14% from the year-ago quarter’s l ...